Status:
WITHDRAWN
Urinary Aquaporine 2 in Patients With Syndrome of Inappropriate ADH-secretion Caused by Treatment With Antiepileptic Medicine
Lead Sponsor:
Regional Hospital Holstebro
Conditions:
Syndrome of Inappropriate ADH-secretion
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Patients treated with the antiepileptic drug Oxcarbazepine often develop syndrome of inappropriate secretion of antidiuretic hormone(SIADH)We want to test the hypothesis, that these patients have a hi...
Detailed Description
The purpose of the study is to determine the amount of Aquaporine2(AQP2)in the urine in patients treated with the antiepileptic drug Oxcarbazepine before and after the administration of fluid restrict...
Eligibility Criteria
Inclusion
- Age more than 18 years, both men and women, patients with epilepsia treated with Oxcarbazepine, and a Sodium content in plasma lower than 130 mmol/liter
Exclusion
- severe diseases in the heart, lungs or liver;diabetes mellitus, other not-well treated diseases in endocrine organs, cancer; unwillingness to participate
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00298753
Start Date
May 1 2005
Last Update
September 15 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Medicine, Holstebro Hospital
Holstebro, Jutland, Denmark, 7500